BSX · Boston Scientific Corp
Price
Snapshot
50 fields · last close| Market Cap | $64.33B |
| P/E | 17.51 |
| Float | 1.48B |
| Beta | 0.59 |
| Volatility | 14.7% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 75.4 |
| Price | 44.74 |
| Change | +0.79% |
| Prev Close | 44.39 |
| Open | 44.45 |
| Day Low | 43.89 |
| Day High | 44.83 |
| Avg Vol | 15 |
| Avg $ Vol | $663.0M |
| 52W High | 105.65 |
| 52W Low | 41.38 |
| 52W Pos | 5.2% |
| From High | −57.65% |
| From Low | +8.11% |
| Max DD 1Y | −60.39% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +2.97% |
| SMA 50 | −2.92% |
| SMA 200 | −24.09% |
| RSI (14) | 52.5 |
| Vol 30D | 32.9% |
| Vol 90D | 33.6% |
| 1Y Range | 41–106 |
| Daily bars | 537 |
| Perf Week | +3.88% |
| Perf Month | +1.93% |
| Perf Quarter | +1.42% |
| Perf Half Y | −27.22% |
| Perf Year | −54.60% |
| Perf YTD | −52.76% |
| Prev Day | +0.79% |
| Clavix | B |
| Debt / Eq | 0.16 |
| Curr Ratio | 1.62 |
| Int Cover | 10.6× |
| FCF Margin | 18.2% |
| Rev Growth | +19.9% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 29 / 49 |
What BSX does
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems.
The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems.
In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer.
The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Clavix risk grade
regraded every trading dayBSX grades B, 75.4 of 100. Steadiest on Macro Resilience (70), most exposed on Sector Resilience (58, mixed). 2 of the 4 weighted dimensions sit above the Health Care median. Ranks 29 of 49 in Health Care by Clavix score.
How rough the ride is
| BSX | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.59 | 0.84 |
| Volatilityannualized | 14.7% | 20.9% |
| Max drawdown, past yearworst peak-to-trough fall | −60.4% | — |
| Typical daily movemedian absolute daily change | 1.18% | — |
| Days beyond ±3%of the last 252 sessions | 30 (12%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| BSX | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.59 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| BSX | |
|---|---|
| 1 week | +3.9% |
| 1 month | +1.9% |
| Year to date | −52.8% |
| 1 year | −54.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| BSX | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 16 Sep |
| Average score0 most bearish, 100 most bullish | 46 |
| Bullish · bearisharticles above 60 · below 40 | 11 · 12 |
| Directionarticles whose tone is improving vs worsening | 11 ↑ 12 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| BSX | |
|---|---|
| Revenue growthyear over year | +19.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openBoston Scientific is voluntarily recalling 262,686 Imager II Angiographic Catheters worldwide because the catheter tip may fracture or detach during use, creating a risk of life-threatening complications for patients. The recall covers current hospital and clinic inventories of the device, which is used in cardiovascular procedures.
A Reddit user explains their bet against Penumbra (PEN) using put options, arguing that Boston Scientific's $374-per-share acquisition of Penumbra will fail. The poster notes that on March 16, 2026, both BSX and PEN received a 'Second Request' from the FTC for additional information, a signal of regulatory scrutiny that often signals antitrust concerns in merger reviews.
Boston Scientific has sued Johnson & Johnson subsidiary Atraverse Medical, alleging that a cardiology device infringes Boston Scientific's patents. Boston Scientific is asking the court for relief that could prevent Atraverse Medical from making or selling the contested device.
Boston Scientific has sued a Johnson & Johnson subsidiary called Atraverse, claiming its Hotwire cardiology device infringes Boston Scientific's patents. The company is asking the court to block sales of the device and to award it financial compensation.
Boston Scientific said Joseph M. Fitzgerald, currently head of its Cardiovascular business, will become chief operating officer on January 1, 2027. The company also announced it will break its business into three reporting segments: Interventional Therapies, Rhythm (the rest of the headline was cut off).
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| COR | Cencora Inc | B+ | $65.06B | 24.79 | 0.58 | Compare |
| CAH | Cardinal Health Inc | A- | $58.83B | 34.32 | 0.54 | Compare |
| BDX | Becton Dickinson and Co | A- | $52.23B | 55.45 | 0.24 | Compare |
| CI | Cigna Group | A- | $79.88B | 12.45 | 0.25 | Compare |
| VEEV | Veeva Systems Inc | B- | $50.25B | 49.52 | 0.88 | Compare |
| EW | Edwards Lifesciences Corp | A- | $49.92B | 49.67 | 0.84 | Compare |
| HUM | Humana Inc | B | $49.61B | 38.79 | 0.67 | Compare |
| MDLN | Medline Inc | B | $47.28B | 68.22 | 0.95 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.